Bulent Yildiz

Dr. Bulent Yildiz


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Asian Biomedicine
Verified
Journal Article
Open access
PDF file
BYBulent Yildiz
Bulent Yildiz
HKHalil Kavgaci
Halil Kavgaci
EFEvren Fidan
Evren Fidan
EGErdal Gungor
Erdal Gungor
HEHalil O. Ersoz
Halil O. Ersoz
FAFazil Aydin
Fazil Aydin
Background: Severe hyperlipidemia secondary to capecitabine, an oral fluoropyrimidine, is a very rare condition. There are no reported cases of hyperlipidemia associated with Uracil/tegafur (UFT). Objective: Report UFT-induced severe hyperlipidemia. Method: A 71-year-old male patient with metastatic colorectal cancer receiving capecitabine treatment was hospitalized at the end of the eighth cycle with the complaint of fatigue. Capecitabine treatment was discontinued in the patient in whom severe hyperlipidemia was detected together with disease progression. Gemphibrozile 1200 mg/day was initiated; patient’s triglyceride level and serum cholesterol decreased from 1768 to 149 mg/dL and from 497 to 99 mg/dL, respectively, five weeks later. The patient started to receive UFT chemotherapy and after the second cycle, he presented to our hospital again with the complaints of fatigue, headache, and yellow vision. The investigations revealed a serum triglyceride level of 4115 mg/dL and a cholesterol level of 734 mg/dL. Results: UFT chemotherapy was discontinued and lipopheresis was administered for three consecutive days, and gemphibrozile was initiated again at a dose of 1200 mg/day. The clinical presentation might be due to oral fluoropyrimidine. Three weeks later, serum cholesterol and triglyceride levels decreased to 106 and 403 mg/dL, respectively. Conclusion: This case is a unique case of hyperlipidemia secondary to UFT. Monitoring of lipid levels, when using Fluoropyrimidine, as well as hemograms, liver and renal functions would be appropriate.

1 January 2011
Verified
Journal Article
Closed access
BYBulent Yildiz
Bulent Yildiz
EFEvren Fidan
Evren Fidan
KYKadriye Yildiz
Kadriye Yildiz
FAFazil Aydin
Fazil Aydin

10 June 2014 in Balkan Medical Journal
Verified
Journal Article
Closed access
BYBulent Yildiz
Bulent Yildiz
EFEvren Fidan
Evren Fidan
FOFeyyaz Ozdemir
Feyyaz Ozdemir
OSOrhan Sezen
Orhan Sezen
HKHalil Kavgaci
Halil Kavgaci
FAFazil Aydin
Fazil Aydin
Triple-negative (TN) breast cancer is a subtype of breast cancer characterised by a loss of estrogen receptor (ER), progesterone receptor (PR) expression, and the absence of human epidermal growth factor (HER2) overexpression. To identify the relationships between clinicopathological characteristics of TN breast cancers in the northeast region of Turkey and disease free survival (DFS) and overall survival (OS). Retrospective clinical study. Seven hundred and eighty non-metastatic breast cancer patients were enrolled in this study. The relationships between TN breast cancer and other breast cancers with respect to clinicopathological characteristics, as well as DFS and OS, were studied. The triple-negative phenotype was detected in 204 patients (27.1%). Patients with triple-negative breast cancer had more grade 2-3 tumours compared to those with other types of breast cancer (92.5% versus 84.3%, p=0.004). Invasive ductal carcinoma histology, on the other hand, was less prevalent in patients with TN breast cancer (77% versus 84.5%, p=0.016). No significant differences were identified between the groups in other clinicopathological variables. Relapse and mortality rates were higher in the TN group during the follow-up of both groups [57 (27.9%) versus 89 (16.2%), p<0.001 for relapse; 27 (13.2%) versus 37 (6.8%), p=0.005 for mortality]. The univariate analysis demonstrated shorter DFS and OS for patients with TN breast cancer compared to those with other types of breast cancer. In the multivariate analysis, patients with TN breast cancer were 2.21 times more likely to develop relapse, while the likelihood of death increased 3.21-fold (p<0.001 and p<0.001). Triple-negative breast cancers demonstrate a more aggressive clinical course compared to other breast cancers. More effective strategies should be developed for the treatment of this subgroup of breast cancer.

6 June 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
OAOrhun Akdoğan
Orhun Akdoğan
YKYasemin Sağdıç Karateke
Yasemin Sağdıç Karateke
İOİlknur Deliktaş Onur
İlknur Deliktaş Onur
GUGalip Uyar
Galip Uyar
OSOsman Sutcuoglu
Osman Sutcuoglu
Short-term mortality following the last dose of immune checkpoint inhibitors (ICIs) is an increasingly recognized real-world outcome measure, yet its clinical predictors remain poorly characterized. This multicenter retrospective study included 458 consecutive patients with advanced melanoma, non-small cell lung cancer, or renal cell carcinoma who received ICIs at four tertiary centers in Turkey between 2018 and 2023. The primary endpoint was 30-day mortality after the final ICI dose. Among 458 patients, 71 (15.5%) died within 30 days. Multivariable logistic regression identified ECOG performance status ≥ 2, number of metastatic sites ≥ 3, and log-transformed C-reactive protein-to-albumin ratio (log-CAR) as independent predictors of 30-day mortality in Model 1 (AUC 0.954), while ECOG PS ≥ 2, brain metastasis, metastatic sites ≥ 3, and log-NLR were independent predictors in Model 2 (AUC 0.912). In the lung cancer subgroup, log-CAR and NLR remained independent predictors while ECOG PS did not. Patients who died within 30 days had significantly shorter progression-free survival (1.18 vs. 4.63 months) and overall survival (2.30 vs. 14.39 months) compared with survivors. These findings suggest that routine assessment of inflammatory and nutritional biomarkers alongside tumor burden parameters may help identify patients at high risk of early mortality and inform the timing of supportive care in ICI-treated populations.

1 January 2010 in The Korean Journal of Pathology
Verified
Journal Article
Open access
PDF file
BYBulent Yildiz
Bulent Yildiz
ARAbdulkadir Reis
Abdulkadir Reis
EFEvren Fidan
Evren Fidan
FOFeyyaz Ozdemir
Feyyaz Ozdemir
HKHalil Kavgaci
Halil Kavgaci
FAFazil Aydin
Fazil Aydin

18 October 2025 in Indian Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
EYEmel Yaldır
Emel Yaldır
IBIşıl Bağcı
Işıl Bağcı
BBBartu Badak
Bartu Badak
BYBulent Yildiz
Bulent Yildiz